Synexa Life Sciences, a specialist biomarker and bioanalysis service provider, announces the acquisition of Alderley Analytical Ltd, based in Manchester, UK. The transaction marks an important milestone in Synexa’s ‘buy and build’ growth strategy, underpinning the company’s vision to be ‘the scientific partner of choice for biomarker and bioanalytical solutions’.
Alderley Analytical’s CRO services complement Synexa Life Sciences’ established capabilities in biomarker and bioanalytical assays—covering DNA, RNA, protein, cell, and tissue analysis.
Alderley Analytical is specialized in mass spectrometry and ligand binding assays, and offers a full range of bioanalytical services to support projects in small molecules, large molecules, peptides, oligonucleotides and biomarkers. The company recently moved to a state-of-the art laboratory in Manchester, UK and is a GLP/GCP accredited laboratory.
Emile Lens, CEO of Synexa Life Sciences, commented: “Welcoming Alderley Analytical to our group is a pivotal step in Synexa’s growth strategy, enhancing our capabilities in bioanalytical services and strengthening its position as a leading European specialist biomarker and bioanalysis services company. By combining two complementary companies, the group now offers a comprehensive range of services to an enlarged customer base. Both in large and small molecule drug development, ranging from pre-clinical work all the way to phase III clinical projects. We are thrilled to welcome the Alderley team to Synexa and look forward to combing our strengths.”
Paul Holme, CEO and Founder of Alderley Analytical, commented: “We are thrilled to join forces with Synexa Life Sciences. This step represents a significant opportunity to enhance our teams’ bioanalytical services and broaden our impact on drug development. We are excited by the new possibilities of providing greater value to our customers and supporting the further advancement of innovative therapies.”
Tom Klein Robbenhaar, Partner at Gilde Healthcare, commented: “Adding the LC/MS capabilities of Alderley to the existing broad bioanalytical capabilities of Synexa is a great and complementary addition for both clients and employees. We are excited to partner with the Alderley team, invest in the Manchester operations and combine Alderley’s and Synexa’s scientific excellence. This is a great acquisition for Synexa and we look forward to team up with more leading bioanalytical service providers.”
About Synexa Life Sciences
Synexa Life Sciences is a global provider of biomarker and bioanalytical services, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays. Our main areas of expertise include biomarker identification and development, clinical bioanalysis, soluble biomarker analysis (utilising MSD, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry and ELISpot) and genomic services to support clinical trials and translational studies.
We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis. We partner with our customers to contribute to the furtherment of scientific development and, ultimately, better management and treatment of human health.
Synexa Life Sciences is backed by Gilde Healthcare, the leading European specialist healthcare investment firm.
About Alderley Analytical
Alderley Analytical is an independent Contract Research Organisation (CRO) specialising in bioanalytical services to support drug development through discovery, pre-clinical safety testing, and clinical development. As a GLP and GCP-accredited laboratory, Alderley Analytical offers regulatory compliance and method validation according to current guidelines, providing reliable and accurate bioanalytical results. Their commitment to excellent communication ensures that clients are well-supported and informed throughout the process.
About Gilde Healthcare
Gilde Healthcare is a specialized healthcare investor managing over €2.6 billion across two fund strategies: Private Equity and Venture&Growth. The Private Equity fund of Gilde Healthcare participates in profitable lower mid-market healthcare companies based in North-Western Europe. The Venture&Growth fund of Gilde Healthcare invests in fast growing companies active in digital health, medtech and therapeutics, based in Europe and North America. For more information, visit the company’s website at www.gildehealthcare.com.
